Search Results

You are looking at 161 - 170 of 2,880 items for :

  • Refine by Access: All x
Clear All
Full access

HSR22-143: Outcome Differences Amongst Stage-Matched Inflammatory vs Non-Inflammatory Breast Cancer Patients

Michael Grimm, Kai Johnson, Patrick Schnell, Ashley Pariser, Margaret Gatti-Mays, Jeffrey VanDeusen, Nicole Williams, Daniel Stover, Sagar Sardesai, Robert Wesolowski, Preeti Sudheendra, Bhuvaneswari Ramaswamy, Ko Un Park, Sachin R Jhawar, Amy Kerger, and Mathew A Cherian

characteristics, treatment regimens, and survival outcomes between non-metastatic IBC patients and comprehensively matched patients with stage III invasive non-IBC based on age, stage, and biomarker status. Results : A total of 165 patients (84 IBC, 81 non

Full access

EPR24-107: Disparities in Colorectal Cancer Mortality Outcomes: A Ten-Year Trend Study

Ayobami Olafimihan, Inimfon Jackson, Stanley Ozogbo, Jeremiah Bello, Praise Fawehinmi, Hafeez Shaka, and Michael Mullane

in inpatient CRCa outcomes. Methods: This is a retrospective longitudinal trends study using the Nationwide Inpatient Sample (NIS) database (2010–2019). We identified hospitalizations with CRCa using ICD-9 and ICD-10 codes and obtained the

Full access

BPI20-009: Impact of Preoperative Biliary Drainage on Postoperative Outcome for Obstructive Jaundice Patients

Zhihui Gao, Shen Sheng, Liu Han, Ni Xiaoling, Suo Tao, Wang Yueqi, and Houbao Liu

Background and aim: Indications of preoperative biliary drainage (PBD) for malignant obstructive jaundice are still controversial. The present study aims to assess the impact of preoperative biliary drainage on postoperative outcome, to define the

Full access

Leveraging Surgical Case Volume in Improving Cancer Care Outcomes: Where Do We Go From Here?

Henry Soo-Min Park

Over the course of the past quarter century, an increasing number of observational studies have been published investigating how surgeon and hospital experience can influence the outcomes of patients undergoing complex surgeries. Early studies

Full access

CLO23-046: Pooled Outcomes of Anti-BRAF Agents in Advanced Stage Colorectal Cancer

Mackenzie Taychert, Ankita Aggarwal, David Tabagari, Urja Nagadia, Sai Gajagowni, Venkata Vosuri, and Kushal Naha

Introduction: BRAF mutations in advanced stage colorectal cancers are observed in 8-12% of patients and BRAF V600E is the most frequent alteration. This mutation confers poor prognosis and treatment outcomes with routine systemic chemotherapy

Full access

CLO24-090: Demographics and Outcomes of Autologous Stem Cell Transplant Among IgD Multiple Myeloma Patients

Nishanth Thalambedu, Phillip Farmer, Clyde Bailey, Lakshmi Yarlagadda, Samer Al-Hadidi, Sharmilan Thanendrarajan, Maurizio Zangari, Carolina Schinke, and Frits VanRhee

analyze the outcomes among IgD MM patients who underwent upfront ASCT (ASCT within 12 months of diagnosis) at our institution. Methods: We conducted a retrospective study among patients with IgD MM and underwent upfront ASCT at the University of Arkansas

Full access

A Survey of the National Comprehensive Cancer Network on Approaches Toward Addressing Patients’ Transportation Insecurity

Krisda H. Chaiyachati, Diana Krause, Jessica Sugalski, Evan M. Graboyes, and Lawrence N. Shulman

widened racial and income disparities in cancer treatment outcomes. 19 – 21 Although national organizations such as the National Academies of Sciences, Engineering, and Medicine have identified transportation insecurity as a key social risk factor, 22

Full access

Stereotactic Ablative Radiotherapy for Non–Small Cell Lung Cancer: Rationale and Outcomes

Puneeth Iyengar and Robert D. Timmerman

To understand why radiation oncologists moved toward the use of SABR in treating primary NSCLCs and metastatic disease to the lungs, the poor outcomes in controlling these disease states with fractionated radiation therapy (eg, 25–37 daily treatments

Full access

Associations Between Medicaid Insurance, Biomarker Testing, and Outcomes in Patients With Advanced NSCLC

Cary P. Gross, Craig S. Meyer, Sarika Ogale, Matthew Kent, and William B. Wong

in survival over the past decade. 2 Advances in personalized therapies for advanced NSCLC (aNSCLC), which allow treatment based on the genetic makeup of a tumor, have significantly contributed to the improved outcomes of patients. 2 Despite the

Full access

Testicular Cancer Survivorship

Chunkit Fung, Paul C. Dinh Jr, Sophie D. Fossa, and Lois B. Travis

long-term adverse health outcomes (AHOs) among TCS is critically important for the development of risk-stratified, evidence-based follow-up guidelines. A multi-institutional study 40 among North American TCS (median age, 37 years) after cisplatin